06:10 AM EDT, 08/17/2026 (MT Newswires) -- Oncopeptides (ONCO.ST) said Monday that Slovenia's medicinal products and medical devices regulator endorsed a maximum allowed price for Pepaxti in patients with multiple myeloma. The pricing determination by the Public Agency of the Republic of Slovenia for Medicinal Products and Medical Devices is a prerequisite for the Swedish biotech company to start formal market access and reimbursement negotiations with the Health Insurance Institute of Slovenia. Oncopeptides noted that Slovenia is a key reference pricing market in the Central and Eastern Europe region.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.